Key Highlights

• Theravance Biopharma (NASDAQ: TBPH) will be acquired by Zymeworks in a $929 million cash and contingent value right transaction.

• Shareholders will receive $17.00 per ordinary share in cash, plus one contingent value right (CVR) per share.

• The deal includes a $32.515 million termination fee payable by either party under specified conditions.

• Closing is anticipated after fulfillment of required regulatory and shareholder approvals.

Deal Terms Announced

Theravance Biopharma Inc. (NASDAQ: TBPH) has signed a definitive agreement to be purchased by Zymeworks Inc. In a transaction valued at $929M. The consideration proposes a cash payment of $17.00 for each ordinary share together with a contingent value right (CVR) that may provide additional upside linked to future asset monetization.

Structure and Consideration

Each Theravance Biopharma ordinary share, carrying a par value of $0.00001, will be exchanged for the cash amount and a CVR. The CVR grants holders a pro rata share of 80% of net proceeds that may arise from licensing or divestiture activities involving designated assets.

Regulatory and Shareholder Hurdles

The transaction requires the assent of holders representing at least two‑thirds of the outstanding ordinary shares of Theravance Biopharma. In addition, clearance from the relevant antitrust authorities is needed before the merger can be consummated.

Termination Provisions

If the agreement is terminated because Theravance Biopharma accepts a superior proposal, the company must remit a termination fee of $32.515 million. Conversely, Zymeworks would be obligated to pay the same sum if the merger does not close within the agreed timeframe due to unmet regulatory conditions.

Financing and Timing

Zymeworks has arranged debt financing through OMERS Life Sciences to fund the purchase price. The parties anticipate that the transaction will be finalized once all regulatory and shareholder conditions have been satisfied.

Contingent Value Rights Details

The CVRs will be governed by a separate agreement, are non‑transferable except under limited circumstances, and do not convey voting rights, dividends, or equity interests in Zymeworks or its affiliates. Their purpose is to provide a contractual claim to future payments tied to specified outcomes.

Board and Fiduciary Duties

Theravance Biopharma’s board retains the ability to evaluate alternative proposals that may be deemed superior, consistent with its fiduciary responsibilities and any notice obligations. The agreement restricts the company from actively seeking competing offers unless specific criteria are met.

Industry Context

The biopharmaceutical sector has seen a surge in strategic consolidations as companies aim to broaden pipelines and enhance financial resilience. Acquisitions featuring cash components coupled with contingent value rights have become a common structure, allowing sellers to benefit from potential upside while providing buyers with flexibility. This deal reflects broader market dynamics where specialty firms seek to integrate complementary technologies and assets, positioning the combined entity for accelerated development of innovative therapies.

Outlook

Assuming successful completion, the merged organization is expected to leverage Zymeworks’ platform capabilities alongside Theravance Biopharma’s product portfolio to advance its pipeline and expand market reach. Stakeholders will monitor regulatory developments and integration progress closely, as these factors will shape the ultimate value realized from the transaction.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.